Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#61 / 200 Total
GP - GreenPower Motor Company Inc - Stock Price Chart
TickerGP [NASD]
CompanyGreenPower Motor Company Inc
CountryCanada
IndustryFarm & Heavy Construction Machinery
Market Cap13.86MEPS (ttm)-0.82
P/E-EPS this Y3.72%
Forward P/E-EPS next Y25.26%
PEG-EPS past 5Y-16.66%
P/S0.67EPS next 5Y26.82%
P/B6.48EPS Q/Q10.60%
Dividend-Sales Q/Q-11.51%
Insider Own22.37%Inst Own2.02%
Insider Trans0.00%Inst Trans-1.66%
Short Float2.46%EarningsFeb 18/b
Analyst Recom1.50Target Price2.08
Avg Volume143.72K52W Range0.45 - 2.00
GreenPower Motor Co., Inc. engages in the manufacture and distribution of all-electric commercial and transit, school, and charter buses. The company was founded by Fraser Atkinson and Phillip W. Oldridge on September 18, 2007 and is headquartered in Vancouver, Canada.
NRIX - Nurix Therapeutics Inc - Stock Price Chart
TickerNRIX [NASD, RUT]
CompanyNurix Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap794.54MEPS (ttm)-2.89
P/E-EPS this Y-12.94%
Forward P/E-EPS next Y-4.27%
PEG-EPS past 5Y-38.86%
P/S14.57EPS next 5Y-5.21%
P/B1.51EPS Q/Q2.70%
Dividend-Sales Q/Q-12.37%
Insider Own1.99%Inst Own108.20%
Insider Trans-3.74%Inst Trans36.56%
Short Float16.36%EarningsJan 28/a
Analyst Recom1.33Target Price31.22
Avg Volume812.76K52W Range11.38 - 29.56
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van Houte HansChief Financial OfficerMar 03 '25Sale14.495,82584,38833,724Mar 03 05:29 PM
JOHANNES VAN HOUTEOfficerMar 03 '25Proposed Sale15.455,82589,996Mar 03 04:17 PM
Ring ChristineChief Legal OfficerJan 31 '25Option Exercise1.865,76010,71438,298Feb 03 08:03 PM
Ring ChristineChief Legal OfficerJan 31 '25Sale19.955,760114,93432,538Feb 03 08:03 PM
CHRISTINE RINGOfficerJan 31 '25Proposed Sale20.025,760115,286Jan 31 04:33 PM
GPCR - Structure Therapeutics Inc ADR - Stock Price Chart
TickerGPCR [NASD]
CompanyStructure Therapeutics Inc ADR
CountryUSA
IndustryBiotechnology
Market Cap904.61MEPS (ttm)-2.32
P/E-EPS this Y6.55%
Forward P/E-EPS next Y-100.60%
PEG-EPS past 5Y-51.75%
P/S-EPS next 5Y-25.24%
P/B1.05EPS Q/Q-19.36%
Dividend-Sales Q/Q-
Insider Own4.91%Inst Own102.86%
Insider Trans0.00%Inst Trans-3.28%
Short Float12.93%EarningsFeb 27/a
Analyst Recom1.00Target Price78.04
Avg Volume821.59K52W Range17.24 - 62.74
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in February 2019 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stevens Raymond CCHIEF EXECUTIVE OFFICERJun 12 '24Option Exercise0.42150,00063,000793,346Jun 14 08:19 PM
Lin XichenCHIEF SCIENTIFIC OFFICERJun 03 '24Option Exercise0.34106,20036,108191,907Jun 05 07:38 PM
WORX - SCWorx Corp - Stock Price Chart
TickerWORX [NASD]
CompanySCWorx Corp
CountryUSA
IndustryHealth Information Services
Market Cap1.39MEPS (ttm)-2.76
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y30.76%
P/S0.43EPS next 5Y-
P/B0.24EPS Q/Q64.25%
Dividend-Sales Q/Q-16.15%
Insider Own3.32%Inst Own10.94%
Insider Trans0.00%Inst Trans0.37%
Short Float0.42%Earnings-
Analyst Recom-Target Price-
Avg Volume39.28K52W Range0.67 - 4.44
SCWorx Corp. engages in the development of software for healthcare providers. It provides data normalization, application interoperability, and big data analytics. The company was founded by Marc S. Schessel in 2012 and is headquartered in Tampa, FL.
ANNX - Annexon Inc - Stock Price Chart
TickerANNX [NASD, RUT]
CompanyAnnexon Inc
CountryUSA
IndustryBiotechnology
Market Cap198.57MEPS (ttm)-1.01
P/E-EPS this Y-24.46%
Forward P/E-EPS next Y-5.76%
PEG-EPS past 5Y-0.09%
P/S-EPS next 5Y10.70%
P/B0.68EPS Q/Q7.82%
Dividend-Sales Q/Q-
Insider Own13.31%Inst Own90.97%
Insider Trans-0.29%Inst Trans2.58%
Short Float11.69%EarningsMar 03/b
Analyst Recom1.00Target Price14.20
Avg Volume1.50M52W Range1.93 - 7.85
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dananberg JamieCHIEF MEDICAL OFFICERFeb 18 '25Sale2.965,52116,34233,479Feb 20 04:54 PM
ARTIS DEAN RICHARDEVP & CHIEF SCIENTIFIC OFFICERFeb 18 '25Sale2.975,51516,38083,814Feb 20 04:52 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 18 '25Sale2.918,34524,28461,237Feb 20 04:51 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 18 '25Sale2.956,61819,52386,579Feb 20 04:49 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 18 '25Sale2.926,91220,18377,770Feb 20 04:48 PM
SION - Sionna Therapeutics Inc - Stock Price Chart
TickerSION [NASD]
CompanySionna Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap448.30MEPS (ttm)-
P/E-EPS this Y86.26%
Forward P/E-EPS next Y-8.19%
PEG-EPS past 5Y-
P/S-EPS next 5Y45.72%
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own38.70%Inst Own30.36%
Insider Trans25.50%Inst Trans28.29%
Short Float6.43%EarningsMar 20/b
Analyst Recom1.00Target Price38.50
Avg Volume276.89K52W Range10.27 - 25.19
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TPG GP A, LLC10% OwnerFeb 10 '25Buy18.001,125,00020,250,0006,684,962Feb 12 05:21 PM
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 10 '25Buy18.001,125,00020,250,0006,923,365Feb 10 05:04 PM
ORBIMED ADVISORS LLCDirectorFeb 10 '25Buy18.00550,0009,900,0003,704,959Feb 10 04:28 PM
Thompson Peter A.DirectorFeb 10 '25Buy18.00550,0009,900,0003,704,959Feb 10 04:05 PM
Booth BruceDirectorFeb 10 '25Buy18.0060,0001,080,000807,727Feb 10 04:05 PM
AUTL - Autolus Therapeutics plc ADR - Stock Price Chart
TickerAUTL [NASD]
CompanyAutolus Therapeutics plc ADR
CountryUnited Kingdom
IndustryBiotechnology
Market Cap375.23MEPS (ttm)-0.87
P/E-EPS this Y-4.85%
Forward P/E-EPS next Y18.02%
PEG-EPS past 5Y21.36%
P/S37.08EPS next 5Y23.49%
P/B0.88EPS Q/Q76.61%
Dividend-Sales Q/Q-
Insider Own9.70%Inst Own53.77%
Insider Trans0.00%Inst Trans-7.79%
Short Float3.80%EarningsMar 20/b
Analyst Recom1.00Target Price9.89
Avg Volume1.25M52W Range1.52 - 6.31
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martin PuleOfficerSep 16 '24Proposed Sale4.23698,7412,955,674Sep 16 05:02 PM
CNTX - Context Therapeutics Inc - Stock Price Chart
TickerCNTX [NASD]
CompanyContext Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap49.44MEPS (ttm)-0.53
P/E-EPS this Y41.74%
Forward P/E-EPS next Y-28.36%
PEG-EPS past 5Y4.72%
P/S-EPS next 5Y-6.14%
P/B0.52EPS Q/Q91.20%
Dividend-Sales Q/Q-
Insider Own41.67%Inst Own47.51%
Insider Trans0.00%Inst Trans169.62%
Short Float4.54%EarningsMar 20/a
Analyst Recom1.00Target Price5.50
Avg Volume160.37K52W Range0.60 - 2.75
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
GLXG - Galaxy Payroll Group Ltd - Stock Price Chart
TickerGLXG [NASD]
CompanyGalaxy Payroll Group Ltd
CountryHong Kong
IndustryStaffing & Employment Services
Market Cap11.35MEPS (ttm)0.01
P/E116.67EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S23.16EPS next 5Y-
P/B93.75EPS Q/Q-31.37%
Dividend-Sales Q/Q-3.80%
Insider Own-Inst Own0.86%
Insider Trans-Inst Trans0.14%
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume1.12M52W Range0.60 - 16.93
Galaxy Payroll Group Ltd. is a holding company which provides payroll outsourcing services. It also offers employment, consultancy and market research services. The outsourcing services assist its end-users in calculating employees' salaries and the required employer's contributions to social security and housing provident funds as well as individual income tax and any other deductions. The employment services act as the employers of record to employ suitable candidates, who are sourced by their end-users. The consultancy and market research services provides consultation for local policy and delivery of country profile reports. The company was founded by Wai Hong Lao, Yiu Kong But, and Wai Cheung Yeung in April 2013 and is headquartered in Hong Kong.
RVPH - Reviva Pharmaceuticals Holdings Inc - Stock Price Chart
TickerRVPH [NASD]
CompanyReviva Pharmaceuticals Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap28.92MEPS (ttm)-0.90
P/E-EPS this Y20.56%
Forward P/E-EPS next Y13.99%
PEG-EPS past 5Y-
P/S-EPS next 5Y29.90%
P/B35.60EPS Q/Q57.58%
Dividend-Sales Q/Q-
Insider Own10.62%Inst Own22.12%
Insider Trans0.00%Inst Trans-4.16%
Short Float6.84%EarningsMar 31/a
Analyst Recom1.00Target Price9.80
Avg Volume1.53M52W Range0.60 - 4.28
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.
12345678910111220